A Study Evaluating the Safety, Tolerability and Preliminary Efficacy of IBI322 in Subjects With Hematologic Malignancy
Clinical trial NCT04795128 · COMPLETED
Trial details
- NCT number
- NCT04795128
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2021-05-07
- Primary completion
- 2023-08-15
- Enrollment
- 70
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.